Cancer Science & Research

Open Access ISSN: 2639-8478


History of the Clinical Validation of the Prostate Health Index

Authors: Dehayni Y, Tetou M, Khdach Y, Janane A, Ameur A, Alami M.

Prostate cancer has become the most common cancer in men over the age of 50 over the past 20 years, since the introduction of the prostate specific antigen blood test ; Which is recognized as a specific organ marker : with low specificity and sensitivity in the discrimination between prostate cancer and benign prostatic hypertrophy. ProPSA and PSA precursor have been studied as a new marker for accurately detecting prostate cancer.

Our thesis is a systematic review discussing the available literature on the clinical validity of the Prostate Health Index. A systematic search of the electronic databases was carried out, taking into account the period from 2000 to January 2017.

These studies have suggested that p2PSA is the most specific form of PSA, being preferentially expressed in cancerous tissue and being significantly elevated in the serum of men with cancer. 

It is now evident that the measurements of p2PSA, % p2PSA and PHI improve the specificity of the available old tests (PSA and derivatives) in the detection of prostate cancer.
In addition, the increase in PHI values appears to correlate with more aggressive forms of cancer.

Some studies have compared p2PSA and its derivatives with other new biomarkers : they found that p2PSA was significantly more accurate. Indeed, the implementation of these tests in clinical practice has the potential to increase the physician's ability to detect PCa and avoid unnecessary biopsies, while having an effective impact on the cost-effectiveness ratio.

View/Download pdf